Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Over 10,000 patients, caregivers, healthcare professionals, policy makers and the general public from 136 countries have signed the world's only Global Atrial Fibrillation Patient Charter calling for government action to help prevent millions of people from dying or becoming disabled by a stroke caused by Atrial Fibrillation (AF).
People can learn about AF and stroke, and read and sign the Charter, which is available in 22 languages, on the Campaign website,www.signagainststroke.com.
To view Multimedia News Release, go to http://www.multivu.com/players/English/57497-sign-against-stroke/
Ahead of World Stroke Day 2012 (October 29), European Policy Makers have joined over 90 Medical and Patient Organisations, and more than 100,000 people, in supporting the Global Atrial Fibrillation (AF) Patient Charter and calling for National Governments and the World Health Organisation to act to make the prevention of AF-related strokes a priority. The Charter outlines ways to improve the diagnosis and management of AF which, if implemented, could stop thousands of preventable strokes from occurring each and every year.
To view Multimedia News Release, go to http://www.multivu.com/players/English/57497-sign-against-stroke/
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
